Introduction
A common question about ChondroFiller is how the gel stays securely in place inside a joint without being stitched in, given that it is a non-surgical injection rather than an operation. This article explains the science behind its stability, with realistic expectations throughout.
A Non-Surgical Approach
ChondroFiller is a CE-marked, acellular type I collagen hydrogel scaffold delivered as a non-surgical injection into the joint. Unlike surgical procedures, it needs no stitches or mechanical fixation. When injected, the gel conforms naturally to the contours inside the joint, forming a protective, cushioning layer over worn surfaces. It is well suited to accessible lesions and smaller joints, and its minimally invasive nature means patients can typically return to activity sooner than after surgery.
The Science Behind Its Stability
When delivered, ChondroFiller transitions from a liquid into a stable gel within approximately three to five minutes, a process called in-situ gelation. The resulting hydrogel is self-adherent: it forms bonds with the fibrin naturally present in the surrounding cartilage and subchondral bone, anchoring the scaffold in place without requiring sutures or external fibrin glue. Its natural stickiness also helps it adhere to joint surfaces, and the gel adapts to the three-dimensional geometry of the defect.
Research examining the material properties of ChondroFiller confirms that its gel displays particularly pronounced viscous effects compared with other tested materials, with a bi-phasic structure dominated by a non-fibrillar hydrogel that helps it absorb load and remain stable under everyday movement (Weizel et al., 2020, Acta Biomaterialia).
Because joints are constantly in motion, this stability matters. ChondroFiller is collagen-based and has biological potential — it recruits the body's own progenitor cells into the scaffold to support tissue repair — but it is best understood as a supportive, joint-preserving measure rather than a cure or reversal of arthritis. Benefits vary between individuals.
Beyond the Knee
ChondroFiller may be considered in joints beyond the knee. Published clinical experience includes use in the hip and in smaller joints such as the trapeziometacarpal joint. Its soft gel suits delivery through a fine needle with minimal disturbance, less discomfort, and a prompt return to activity compared with open surgical alternatives. A published case series reported significant pain reduction and functional improvement in patients treated at the trapeziometacarpal joint (Corain et al., 2023, Cartilage), illustrating its adaptability across joint types.
Conclusion
ChondroFiller's design allows it to form a stable, adhesive gel that anchors naturally within the defect and remains in place under movement — without stitches, mechanical fixation, or a surgical theatre visit. It may help support a worn joint for some people, but benefits vary and it is not a cure for arthritis. At the London Cartilage Clinic, individual assessment is provided to help patients understand whether a ChondroFiller injection may be appropriate for their situation.
References
- Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.
- Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- Unlike hyaluronic acid or steroid injections, ChondroFiller is a structural collagen scaffold that gels in place within the joint. It stays in position without stitches or fixation, forming a cushioning layer over worn surfaces and providing a matrix that the body's own repair cells can populate. It is not a cure for arthritis, and individual results vary.
- Its gel adheres naturally to the fibrin present in the surrounding cartilage and bone, and moulds to the joint's internal contours. The material's mechanical properties — in particular its pronounced viscous behaviour — help it remain stable under everyday load and movement.
- Yes, it may be considered in several joints including the hip and smaller joints such as the trapeziometacarpal joint, delivered via fine-needle injection. Suitability depends on defect size, location, and individual patient factors, which a specialist can assess.
- No. ChondroFiller is the CE-marked type I collagen hydrogel scaffold material itself. Liquid Cartilage refers to a separate, keyhole surgical protocol developed by Professor Paul Lee, in which ChondroFiller is placed arthroscopically alongside biological adjuncts such as platelet-rich fibrin and, where indicated, mesenchymal stem cells. The ChondroFiller injection described in this article is a non-surgical, outpatient procedure — Liquid Cartilage is a surgical technique.
- No theatre, no general anaesthetic, no stitches, minimal procedural disturbance, and a shorter recovery compared with keyhole or open surgical options. For patients whose defect or joint is suited to the injection approach, this can be a meaningful benefit. A specialist assessment is needed to determine which pathway is appropriate.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
